| Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial R Ella, KM Vadrevu, H Jogdand, S Prasad, S Reddy, V Sarangi, ... The Lancet Infectious Diseases 21 (5), 637-646, 2021 | 462 | 2021 |
| Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a … R Ella, S Reddy, H Jogdand, V Sarangi, B Ganneru, S Prasad, D Das, ... The Lancet Infectious Diseases 21 (7), 950-961, 2021 | 364 | 2021 |
| Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial R Ella, S Reddy, W Blackwelder, V Potdar, P Yadav, V Sarangi, VK Aileni, ... The Lancet 398 (10317), 2173-2184, 2021 | 359 | 2021 |
| SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ... EBioMedicine 87, 2023 | 71 | 2023 |
| WASH practices and its association with nutritional status of adolescent girls in poverty pockets of eastern India A Chattopadhyay, V Sethi, VP Nagargoje, A Saraswat, N Surani, ... BMC women's health 19, 1-13, 2019 | 63 | 2019 |
| The effect of regular physical exercise on the thyroid function of treated hypothyroid patients: An interventional study at a tertiary care center in Bastar region of India A Bansal, A Kaushik, CM Singh, V Sharma, H Singh Archives of Medicine and Health Sciences 3 (2), 244-246, 2015 | 53 | 2015 |
| Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune … R Ella, S Reddy, H Jogdand, V Sarangi, B Ganneru, S Prasad, D Das, ... medRxiv, 2020.12. 21.20248643, 2020 | 48 | 2020 |
| Prevalence of hypertension and its risk factors among school going adolescents of Patna, India P Kumar, D Kumar, A Ranjan, CM Singh, S Pandey, N Agarwal Journal of clinical and diagnostic research: JCDR 11 (1), SC01, 2017 | 43 | 2017 |
| Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and … S Thuluva, V Paradkar, SR Gunneri, V Yerroju, R Mogulla, K Turaga, ... EBioMedicine 83, 2022 | 42 | 2022 |
| A study of knowledge and attitude of adolescent girls towards reproductive health and related problems S Agrawal, A Fatma, CM Singh Indian J Prev Soc Med 38 (1), 2, 2007 | 41 | 2007 |
| Morbidity Profile ofunder five children in urban slums of Etawah District. DK Srivastava, D Tripathi, PK Jain, CM Singh, AK Srivastava, S Kumar, ... Indian Journal of Community Health 24 (2), 2012 | 38 | 2012 |
| Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India C Singh, BN Naik, S Pandey, B Biswas, BK Pati, M Verma, PK Singh Epidemiology & Infection 149, e224, 2021 | 33 | 2021 |
| Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants KM Vadrevu, B Ganneru, S Reddy, H Jogdand, D Raju, G Sapkal, ... Scientific reports 12 (1), 12038, 2022 | 27 | 2022 |
| A phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152 R Ella, KM Vadrevu, H Jogdand, S Prasad, S Reddy, V Sarangi, ... MedRxiv, 2020.12. 11.20210419, 2020 | 27 | 2020 |
| Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS‐CoV‐2 vaccine 1 (BBV152): a, double‐blind, randomised, controlled phase 3 trial R Ella, S Reddy, W Blackwelder, V Potdar, P Yadav, V Sarangi, VK Aileni, ... MedRxiv, 2021 | 25 | 2021 |
| CAR T cell therapy: newer approaches to counter resistance and cost RK Yadav, A Ali, S Kumar, A Sharma, B Baghchi, P Singh, S Das, C Singh, ... Heliyon 6 (4), 2020 | 25 | 2020 |
| Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation … KM Vadrevu, S Reddy, H Jogdand, B Ganneru, N Mirza, VN Tripathy, ... The Lancet Infectious Diseases 22 (9), 1303-1312, 2022 | 24 | 2022 |
| Acute necrotizing encephalitis as a probable association of COVID-19 N Kumar, S Kumar, A Kumar, BK Pati, A Kumar, C Singh, A Sarfraz Indian journal of critical care medicine: peer-reviewed, official …, 2020 | 23 | 2020 |
| Diabetes and quality of life—A pilot study P Kumar, N Agarwal, CM Singh, S Pandey, A Ranjan, D Kumar Int J Med Sci Public Health 5 (6), 1143-47, 2016 | 23 | 2016 |
| E cacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial R Ella, S Reddy, W Blackwelder, V Potdar, P Yadav, V Sarangi, VK Aileni, ... Lancet 398 (10317), 2173-84, 2021 | 22 | 2021 |
Sanjay K. PandeyChief Scientific Officer, Triangulum Biopharma, San Diego CA在 triangulumbiopharma.com 的电子邮件经过验证
